•  
  •  
 

Corresponding Author

Ghazala, Ahmed

Document Type

Original Article

Abstract

Background: When proliferative diabetic retinopathy is treated with pars plana vitrectomy, post-operative vitreous bleeding is prevalent. Complications such as these impede visual rehabilitation and may demand additional surgical treatments. Aim of the Work: An evaluation of efficacy as well as safety of intravitreal ranibizumab prior to Vitrectomy surgery in individuals with diabetes to reduce postoperative bleeding. Patients and Methods: More than one month of persistent diabetic vitreous bleeding was included in this randomized, prospective research. There were two groups of eyes that were considered eligible: Twenty eyes in Group A had no intravitreal injections, while twenty eyes in Group B received a ranibizumab intraoperative intravitreal injection. Results: PDR problems are related with considerable improvement in postoperative BCVA in one week, one month, and three months postoperatively in both group A and group B compared to preoperative BCVA. Postoperative BCVA at 3 months which was 0.953± 0.451 and A statistically significant difference (p = 0.000) was found between the two groups. Conclusion: In patients who got preoperative intravitreal ranibizumab injection, the incidence of postoperative vitreous hemorrhage is lower than in individuals who did not receive IVR injection. There was no statistical significance despite this association, however this is because there were only a few cases in this study.

Keywords

vitrectomy; Vitreous haemorrhage; diabetics

Download

Share

COinS